Patents by Inventor Craig Stephen Mickanin

Craig Stephen Mickanin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20240002843
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: October 13, 2022
    Publication date: January 4, 2024
    Applicants: Novartis AG, Intellia Therapeutics, Inc.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20230118337
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: June 24, 2022
    Publication date: April 20, 2023
    Inventors: Craig Stephen MICKANIN, Christian SCHMEDT, Jennifer SNEAD, Susan C. Stevenson, Yi YANG
  • Compositions and methods for the treatment of hemoglobinopathies
    Patent number: 11466271
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: October 11, 2022
    Assignees: Novartis AG
    Inventors: Craig Stephen Mickanin, Christian Schmedt, Jennifer Snead, Susan Stevenson, Yi Yang
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20200102561
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: February 5, 2018
    Publication date: April 2, 2020
    Inventors: Craig Stephen MICKANIN, Christian SCHMEDT, Jennifer SNEAD, Susan Stevenson, Yi YANG
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190010495
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 26, 2016
    Publication date: January 10, 2019
    Applicants: NOVARTIS AG, INTELLIA THERAPEUTICS, INC.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • BIOMARKERS ASSOCIATED WITH BRM INHIBITION
    Publication number: 20180258491
    Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate FIRM inhibitors, and associated methods of treatment are also provided.
    Type: Application
    Filed: December 22, 2017
    Publication date: September 13, 2018
    Applicant: Novartis AG
    Inventors: Zainab JAGANI, Gregory HOFFMAN, Frank Peter STEGMEIER, Craig Stephen MICKANIN
  • Biomarkers associated with BRM inhibition
    Patent number: 9850543
    Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Zainab Jagani, Gregory Hoffman, Frank Peter Stegmeier, Craig Stephen Mickanin
  • BIOMARKERS ASSOCIATED WITH BRM INHIBITION
    Publication number: 20160032402
    Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 4, 2016
    Applicant: Novartis AG
    Inventors: Zainab JAGANI, Gregory HOFFMAN, Frank Peter STEGMEIER, Craig Stephen MICKANIN
  • Mammary gland chemokine
    Patent number: 6833241
    Abstract: The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: December 21, 2004
    Assignee: Novartis
    Inventors: Mark A. Labow, Craig Stephen Mickanin, Umesh Bhatia
  • Tumor necrosis factor receptor related protein-1 gene and protein
    Publication number: 20030059889
    Abstract: Disclosed is a tumor necrosis factor receptor related protein 1 gene and gene product. In particular, the invention relates to a protein that is homologous to known tumor necrosis factor receptors, nucleic acid molecules that encode such a protein, antibodies that recognize the protein, methods for diagnosing and treating disorders, such as inflammatory disorders, immune disorders, neurodegenerative disorders, cell proliferative disorders, cell differentiation disorders, apoptotic disorders, gastrointestinal and reproductive tract disorders, bone disorders, blood disorders and viral disorders, methods of identifying molecules that bind and/or modulate the activity of TRP-1 protein, and methods of identifying molecules that bind to a nucleic acid encoding TRP-1 protein and/or modulate the transcription or translation of the nucleic acid encoding TRP-1 protein.
    Type: Application
    Filed: August 28, 2002
    Publication date: March 27, 2003
    Inventors: Dale Lesley Bodian, Mark Aron Labow, Craig Stephen Mickanin
  • Mammary gland chemokine
    Publication number: 20020009735
    Abstract: The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.
    Type: Application
    Filed: March 21, 2001
    Publication date: January 24, 2002
    Inventors: Mark A. Labow, Craig Stephen Mickanin, Umesh Bhatia